Skip to content
Back to meeting Original
Oncology Learning Network路 @OncLearnNetwork 路 X路路 2 days agoScore70

rezetecan

Body

馃毃Results from #ARTEMIS011 demonstrated that risvutatug rezetecan significantly improved PFS in heavily pretreated relapsed or refractory #osteosarcoma, supporting a potential new treatment option.

Learn more: https://www.hmpgloballearningnetwork.com/site/onc/news/risvutatug-rezetecan-reduces-progression-risk-67-previously-treated-relapsed-or

#ESMO26 #MedTwitter

9 views 路 0 likes 路 0 reposts 路 0 replies

Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage

Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)

https://esmocongress.esmo.org

Source: Oncology Learning Network 路 x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website鈥檚 feedback page.